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Abstract
Background Several anesthetic agents are used in cesarean sections for both regional and general anesthesia purposes. How-
ever, there are no data comparing the in vivo effects of propofol, sevoflurane, and dexmedetomidine on the contraction of the 
myometrium in pregnant rats. The aim of this study was to investigate the effect of these anesthetic agents on myometrial 
contraction and elucidate the underlying mechanisms.
Methods Contraction force and frequency changes in response to propofol, dexmedetomidine, or sevoflurane were evalu-
ated in vivo and in vitro. To test the effect of arachidonic acid on myometrial contraction enhanced by dexmedetomidine, 
changes in myometrial contraction with dexmedetomidine after administration of indomethacin were evaluated. The amount 
of phosphorylated myosin phosphatase target subunit 1 (MYPT1) in the membrane fraction was expressed as a percentage 
of the total fraction by Western blot analysis.
Results This study demonstrated that dexmedetomidine enhances oxytocin-induced contraction in the myometrium of preg-
nant rats, whereas propofol and sevoflurane attenuate these contractions. The dexmedetomidine-induced enhancement of 
myometrial contraction force was abolished by the administration of indomethacin. Propofol did not affect oxytocin-induced 
MYPT1 phosphorylation, whereas sevoflurane attenuated oxytocin-induced MYPT1 phosphorylation.
Conclusions Inhibition of myofilament calcium sensitivity may underlie the inhibition of myometrial contraction induced 
by sevoflurane. Arachidonic acid may play an important role in the enhancement of myometrial contraction induced by dex-
medetomidine by increasing myofilament calcium sensitivity. Dexmedetomidine may be used as a sedative agent to promote 
uterine muscle contraction and suppress bleeding after fetal delivery.
Keywords Myometrial contraction · Dexmedetomidine · Pregnant rat
Introduction
Several anesthetic agents are used in cesarean sections for 
both regional and general anesthesia purposes. Some anes-
thetic agents have an inhibitory effect on myometrial con-
traction and may cause atonic bleeding [1]. A close cor-
relation between myometrial contraction and postpartum 
hemorrhage during delivery has been reported [2]. Post-
partum hemorrhage is the leading cause of maternal death 
worldwide, responsible for an estimated 100,000 deaths each 
year [3].
Previous studies have reported that volatile anesthetics 
such as sevoflurane exert inhibitory effects on myometrial 
contraction in rats [4–8] and humans [9–12]. Similarly, 
propofol reportedly inhibits myometrial contraction in rats 
[13, 14] and humans [15–17]. Tsujiguchi et al. reported that 
the inhibition of contraction by propofol involves inhibition 
of increases in the intracellular concentration of free  Ca2+. In 
other smooth muscles, for example, vascular smooth muscle 
tone is regulated by changes in both the intracellular  Ca2+ 
concentration and myofilament  Ca2+ sensitivity [18]. Kudo 
et al. reported that contractions in airway smooth muscle 
are regulated by intracellular  Ca2+ influx from the sarco-
plasmic reticulum or from the extracellular environment via 
voltage-dependent  Ca2+ channels (VDCCs) and regulation 
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of calcium sensitivity by the RhoA/Rho kinase pathway 
[19]. In myometrial smooth muscle, muscle tone is report-
edly regulated by changes in intracellular  Ca2+ concentration 
through VDCCs [7], but the involvement of myofilament 
 Ca2+ sensitivity is unclear.
A possible mechanism to explain the change in myofila-
ment  Ca2+ sensitivity involves the inactivation of myosin 
light-chain phosphatase (MLCP) in a process regulated by 
protein kinase C, arachidonic acid, and Rho-kinase. Myosin 
phosphatase target subunit 1 (MYPT1) is a targeting subunit 
of MLCP, and volatile anesthetic agents reportedly inhibit 
the phosphorylation of MYPT1 [20]. The mechanisms 
of inhibition are known to differ within the same class of 
inhalational anesthetic. That is, although both sevoflurane 
and isoflurane reduce vascular contractions, the underlying 
mechanisms differ. Isoflurane regulates contractions by alter-
ing the intracellular  Ca2+ concentration, whereas sevoflurane 
regulates contractions by modulating myofilament  Ca2+ sen-
sitivity [21]. Therefore, we studied the effects of various 
anesthetic agents on myofilament calcium sensitivity and 
myometrial contraction.
Dexmedetomidine is an α2-adrenergic agonist that causes 
minor respiratory depression. α2-Adrenergic agonists cause 
myometrial contraction by inducing an influx of extracellular 
 Ca2+, probably through VDCCs and the release of arachi-
donic acid [22]. Several recent studies reported that dexme-
detomidine is effective for treating postpartum shivering in 
cesarean sections [23–25] and can improve early breastfeed-
ing outcomes [26]. α2-Adrenoceptor activation reportedly 
results in the release of arachidonic acid in vascular smooth 
muscle [27]. Arachidonic acid in turn inhibits MLCP and 
increases the  Ca2+ sensitivity of contractile elements. There-
fore, dexmedetomidine may enhance myometrial contrac-
tion via its inhibitory effect on MLCP in conjunction with 
arachidonic acid. However, there are no data comparing the 
in vivo effects of propofol, sevoflurane, and dexmedetomi-
dine on contraction in the myometrium of pregnant rats. We 
hypothesized that dexmedetomidine augments myometrial 
contraction in pregnant rats while propofol and sevoflurane 
inhibit myometrial contraction. The aim of this study was to 
investigate the effects of these anesthetic agents on myome-
trial contraction and elucidate the underlying mechanisms.
Methods
The effects of dexmedetomidine, propofol, and sevoflurane 
on myometrial contraction in vitro and in vivo were investi-
gated in pregnant rats.
Animals
All experiments involving animals were carried out with 
approval from the Ethics Committee for Animal Research 
of Sapporo Medical University (permit number: 17–60, 93, 
112, 135). Experiments were performed on pregnant Wistar 
rats, 250–280 g, 19–21 days of gestation. Rats were kept at 
24 ± 2 °C under a 12 h/12 h light/dark cycle and maintained 
on a standard pellet diet with tap water available freely.
Drugs
All drugs and solutions were prepared immediately before 
each experiment was performed. Oxytocin (Sigma-Aldrich, 
St. Louis, MO, USA) was added directly to the organ baths 
to a final concentration of 20 nM, with reference to a pre-
vious study [13]. The effects of propofol (Sigma-Aldrich) 
were evaluated at cumulative concentrations of  10−7 M, 
 10−6 M, and  10−5 M. Given that more than 95% of propo-
fol (2–5 × 10−5 M) in the blood is bound to plasma protein 
[28], a free propofol concentration of 4–10 × 10−7 M in vitro 
would be comparable to 9–10 µg/ml of propofol in vivo [29]. 
Because the therapeutic range of plasma propofol is 2–9 µg/
ml, the effective propofol concentrations tested in this study 
were considered close to the free concentrations clinically 
observed in serum. The effects of dexmedetomidine (Marui-
shi, Osaka, Japan) were evaluated at cumulative concentra-
tions of  10−9 M,  10−8 M, and  10−7 M. Ebert et al. reported 
that the therapeutic plasma concentration of dexmedetomi-
dine for sedation ranges from 0.7 to 1.2 ng/ml [30]. Based on 
previous studies, we selected dexmedetomidine concentra-
tions that would reach therapeutic plasma concentrations. 
Sevoflurane (Maruishi) was introduced into the gas mixture 
using agent-specific vaporizers (Vapor 19.3, Dragerwerk, 
Lubeck, Germany). All other reagents used in the experi-
ments were of analytical grade.
Measurement of myometrial contraction
In vitro contraction studies
Pregnant Wistar rats were anesthetized with sevoflurane and 
sacrificed by decapitation. The abdomen of each rat was then 
opened along the midline; subsequently, the uterine horns 
were rapidly excised and carefully cleansed of surrounding 
connective tissues, in reference to previous literature [31]. 
Embryos and the placenta were gently removed, and 2- to 
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3-mm-long uterine rings were sliced from the uterine horns 
and mounted in an organ bath containing 10 mL of Krebs 
solution (118.2 mM NaCl, 4.6 mM KCl, 2.5 mM  CaCl2, 
1.2 mM  MgSO4, 1.2 mM  KH2PO4, 24.8 mM  NaHCO3, 
10 mM dextrose), bubbled with 95%  O2 and 5%  CO2, and 
maintained at 37 °C and a pH of approximately 7.40. As 
shown in Fig. 1, one end of each myometrial strip was con-
nected to a lower hook of the bath, and the other end was 
connected to a balanced point of a force rod. The resting 
tension was set at 2.0 g, which was optimal for inducing 
maximal constriction in our preliminary experiments. Before 
the start of the experiments, the uterine rings were allowed 
to equilibrate for 45 min, during which time the Krebs solu-
tion was replaced every 15 min.
Thirty strips of myometrium were obtained from 15 preg-
nant rats; each of the two of strips taken per rat was ran-
domly assigned to 1 of the 3 groups (n = 10 per group). The 
protocol for in vitro myometrial contraction measurement is 
illustrated in Fig. 2. After equilibration, oxytocin (20 nM) 
was added to the organ bath; the subsequent response served 
as a control (100%). After the control contraction occurred, 
contraction-force and contraction-frequency changes in 
response to propofol  (10−7–10−5 M), dexmedetomidine 
 (10−9–10−7 M), or sevoflurane (2.0, 3.5, 5.0%) were evalu-
ated. In the sevoflurane group, sevoflurane was administered 
via the gas mix (95%  O2 and 5%  CO2). For each concentra-
tion of the anesthetic agent, measurements were recorded 
for 15 min.
The amplitude of contraction force in the uterine rings 
was measured using isometric force transducers (ULA-
10GR, MinebeaMitsumi, Nagano, Japan) and recorded using 
an ML846 PowerLab 4/26 (ADinstruments, Australia). Con-
traction force was measured by calculating the area under the 
curve (AUC) of the tension versus time curve. Contraction 
force and contraction frequency were measured from the 
last 10 min of the 15-min exposure. The effects of anesthetic 
agents are expressed as percentages of the control force and 
frequency of myometrial contraction induced by oxytocin.
Actual values to volatilize volatile anesthetics from organ 
baths and glass slides may differ from theoretical values. 
Therefore, the concentrations of the anesthetic agents in the 
Krebs solution were measured by gas chromatography and 
determined to be 0.27 ± 0.01 mM and 0.58 ± 0.08 mM at 
sevoflurane concentrations of 2.4% and 4.8%, respectively 
(n = 8). It was assumed that the blood concentration of sevo-
flurane was equal to the Krebs solution dissolved sevoflurane 
concentration and that the end-expiratory concentration of 
sevoflurane was equal to the actual dose of sevoflurane, with 
dialed 2.4% and 4.8% of sevoflurane equivalent to 1.0% and 
2.1%, respectively. As sevoflurane volatilized in the organ 
Fig. 1  (A) Photo of actual gestational uterine ring, (B) diagram of 
isolated organ bath system: Isolated organ bath system with an organ 
bath, heating circulator, force transducer and recording system. Uter-
ine rings (2–3 mm) were sliced from the uterine horns and mounted 
vertically in an organ bath containing 10 mL Krebs solution bubbled 
with 95%  O2 and 5%  CO2. The temperature of the organ bath was 
maintained at 37 °C with a heating circulator. The amplitude and fre-
quency of contraction force in the uterine rings were measured using 
an isometric force transducer (ULA-10GR) and recorded using a 
recording system (ML846 PowerLab 4/26)
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bath, its concentration decreased by approximately half of 
the original minimum alveolar concentration (MAC). In a 
study by Yu et al., sevoflurane was delivered into the gas 
mixture via calibrated agent-specific vaporizers to aerate 
the Krebs solution. They concluded that their results would 
provide a valuable reference for clinical anesthesia research 
[32]. In our study, we used an organ bath system that sup-
plied anesthetic agents in an identical manner. Thus, as the 
concentrations were clinically relevant, the findings are con-
sidered meaningful.
In vivo contraction studies
Twenty-four pregnant Wistar rats were anesthetized with 
sevoflurane and subjected to tracheotomy. The tail vein was 
cannulated for intravenous drug administration, and the 
femoral artery was cannulated for measuring blood pressure.
A balloon was constructed to measure myometrial 
contraction using a catheter and rubber (Fig. 3). Next, 
the abdomen of each rat was opened along the midline; 
subsequently, an embryo was gently removed, and the 
balloon was inserted into the myometrium. The wound 
was closed, and the balloon was connected to the pres-
sure transducer.
Figure 4 illustrates the protocol for in vivo myometrial 
contraction measurement. After equilibration of myome-
trial contraction using sevoflurane (3.0%), the anesthetic 
agent was switched to propofol (30 mg/kg/h), dexmedeto-
midine (6 µg/kg/h), or sevoflurane (2.0%) (n = 8 per group). 
Contraction-force and contraction-frequency changes in 
response to the anesthetic agents were then evaluated. After 
15 min of observation, the anesthetic agents were switched 
to propofol (150 mg/kg/h), dexmedetomidine (30 µg/kg/h), 
or sevoflurane (5.0%). A neuromuscular blocking agent, 
rocuronium (Eslax®; MSD Co., Ltd., Tokyo, Japan) was 
administered to the rats at 5 mg/h (continuous intravenous 
infusion) after sedation with an anesthetic agent to exclude 
the effects of skeletal muscles.
Fig. 2  Protocol for in  vitro myometrial contraction measurement 
(n = 10 per group). (A) Protocol for propofol, (B) Protocol for dex-
medetomidine, (C) Protocol for sevoflurane. After equilibration, oxy-
tocin (20 nM) was administered to the organ bath. Contraction-force 
and -frequency changes in response to propofol  (10−7–10−5 M), dex-
medetomidine  (10−9–10−7  M), or sevoflurane (2.0, 3.5, 5.0%) were 
evaluated. In the sevoflurane group, sevoflurane was administered 
into the gas mix (95%  O2 and 5%  CO2). For each concentration of 
anaesthetic agent, recording was performed for 15  min. Force and 
frequency of myometrial contractions were measured from the last 
10 min of the 15-min exposure
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Fig. 3  Balloon developed to 
measure myometrial contrac-
tions using a catheter and rub-
ber. The tip of the catheter was 
covered with rubber, and saline 
was poured inside. The balloon 
was then connected to the pres-
sure transducer
Fig. 4  Protocol for in  vivo myometrial contraction measurement 
(n = 8 per group). (A) Protocol for propofol, (B) Protocol for dexme-
detomidine, (C) Protocol for sevoflurane. Pregnant rats were anesthe-
tized with sevoflurane subjected to tracheostomy, after which vascu-
lar access was obtained and the balloon was inserted in the uterus to 
measure myometrial contractions. Contraction-force and -frequency 
changes in response to propofol (30, 150  mg/kg/h), dexmedetomi-
dine (6, 30 μg/kg/h), or sevoflurane (2, 5%) were evaluated. For each 
concentration of each anesthetic agent, recording was performed for 
15 min. Force and frequency of myometrial contractions were meas-
ured from the last 10 min of the 15-min exposure
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Involvement of arachidonic acid in the effect 
of dexmedetomidine on myometrial contraction
Indomethacin is a non-steroidal anti-Inflammatory drug that 
inhibits the arachidonic acid cascade by inhibiting the activity 
of cyclooxygenase. To examine the effect of arachidonic acid 
on myometrial contraction enhanced by dexmedetomidine, 
changes in myometrial contraction with dexmedetomidine 
after administration of indomethacin were evaluated. Indo-
methacin (5 mg/kg) was administered by intravenous infusion 
when the anesthetic agent was changed to dexmedetomidine.
Western blot analysis
The relationship between the effects of sevoflurane or propo-
fol on uterine muscle contraction and MYPT1 activity was 
investigated using Western blot analysis. Pregnant Wistar 
rats were anesthetized with sevoflurane and sacrificed by 
decapitation. Myometrial tissue strips were collected and 
treated with oxytocin in the presence or absence of propofol 
 (10−5 M), sevoflurane (5.0%), or Y27632 (Rho-kinase inhibi-
tor)  (10−5 M) for 15 min. After treatment, myometrial tissue 
strips were homogenized in ice-cold lysis buffer containing 
HEPES (2-[4-(2-Hydroxyethyl)-1-piperadinyl] ethane sul-
fonic acid) (50 mM), adjusted to a pH of 7.5, Triton X-100 
(1%), NaCl (50 mM), NaF (50 mM), EDTA (5 mM), sodium 
pyrophosphate (10 mM), phenylmethanesulfonyl fluoride 
(1 mM),  Na3VO4 (1 mM), leupeptin (100 µg/mL), and apro-
tinin (10 µg/mL). Homogenates were centrifuged at 1.0 × 104 g 
for 15 min at 4 °C, and the supernatant was collected. The pro-
tein concentration of each supernatant was determined using 
a Pierce BCA Protein Assay kit (Thermo Fisher Scientific 
K.K., Yokohama, Japan). Equal amounts of total protein were 
used for every sample in each experiment. Strips were treated 
with anti–β-actin antibody (1:1000) as a loading control. Pro-
teins were separated by 7.5% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis and blotted onto nitrocellulose 
membranes. The membranes were treated with anti-MYPT1 
antibody (1:1000) and anti-phosphorylated MYPT1 antibody 
(1:1000). The densities of the immunoreactive bands were 
determined using enhanced chemiluminescence (Amersham 
Pharmacia Biotech, Piscataway, NJ, USA), and the data were 
analyzed using an image analysis system (ATTO Corporation, 
Tokyo, Japan). The amount of phosphorylated MYPT1 in the 
membrane fraction is expressed as a percentage of the total 
fraction.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (ver-
sion 7.00, GraphPad Software, San Diego, CA, USA). For 
statistical evaluations, data were analyzed by paired t-tests or 
one-way ANOVA with Tukey’s multiple comparisons test. P 
values < 0.05 were considered significant.
Results
In vitro contractility studies
All uterine strips demonstrated spontaneous contraction in 
the organ baths. Figure 5 shows typical traces of uterine con-
tractions in the organ bath experiments with oxytocin and 
after the addition of different concentrations of anesthetics. 
The frequency of myometrial contraction was significantly 
decreased by all anesthetic agents. Although the AUCs were 
significantly decreased by propofol and sevoflurane, no sig-
nificant difference between any concentration was observed 
with dexmedetomidine (Fig. 6).
In vivo contractility studies
There was no difference in the frequency of myometrial con-
traction induced by any anesthetic agent between the two 
concentrations examined. The higher concentration of dex-
medetomidine significantly enhanced the myometrial con-
traction force (Fig. 7). The administration of indomethacin 
abolished the dexmedetomidine-induced enhancement of 
myometrial contraction force (Fig. 8).
Western blot analysis
Oxytocin significantly increased the ratio of phosphorylated 
MYPT1 to total MYPT1 (n = 6 in each group, MD − 0.8, 
95% CI − 1.5 to − 0.1, P < 0.05). Propofol did not affect 
oxytocin-induced MYPT1 phosphorylation (n = 6 in each 
group, MD − 0.1, 95% CI − 0.8 to 1.0, P = 0.99), whereas 
sevoflurane attenuated oxytocin-induced MYPT1 phospho-
rylation (n = 6 in each group, MD 1.1, 95% CI 0.4 to 1.8, 
P < 0.05) (Fig. 9). β-Actin exhibited no significant differ-
ences between groups.
Discussion
In this study, we demonstrated the effects of dexmedetomi-
dine, propofol, and sevoflurane on myometrial contraction 
both in vitro and in vivo. We also demonstrated the effect of 
these anesthetics on the  Ca2+ sensitivity of the myometrial 
contraction mechanism.
In our in  vitro study, although the contraction force 
induced by oxytocin was significantly decreased by propofol 
and sevoflurane, no significant difference was observed with 
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dexmedetomidine. All three anesthetic agents significantly 
decreased the frequency of myometrial contraction. Previous 
studies found that propofol reduces oxytocin-induced con-
traction force and frequency in myometrium isolated from 
rats [13] and humans [17]. Tsujiguchi et al. showed that 
 10−5 M propofol suppressed the 20 nM oxytocin-induced 
peaks of myometrial contraction by approximately 40%. 
Interestingly, in the present study,  10−5 M propofol reduced 
the AUC in the 20 nM oxytocin-induced contraction group 
by 23%. It is difficult to compare these results, however, 
because the index of myometrial contraction differed, but 
both results suggest that propofol suppresses myometrial 
contraction.
Other studies have found that sevoflurane reduces the 
force and frequency of oxytocin-induced myometrial 
contraction in myometrium isolated from humans [10] and 
rats [4, 6]. Dogru et al. reported that the highest measured 
levels of inhibition of the amplitude and frequency of myo-
metrial contractions with sevoflurane (at 2 MAC) were 84% 
and 75%, respectively. Although there were methodologic 
differences between that study and our, such as related to the 
concentration of oxytocin and the index of contraction, these 
results were similar to those of the present study.
Previous studies have also found that dexmedetomi-
dine augments spontaneous myometrial contraction in 
myometrium isolated from humans [33] and rats [31, 34]. 
Semra et al. reported that dexmedetomidine at  10−9 M, 
 10−7 M, and  10−5 M significantly increased the ampli-
tude, frequency, and AUC of myometrial contraction 
compared with baseline and control samples. However, 
Fig. 5  Typical traces of uterine contractions in the organ bath experiments with oxytocin (A) and after the addition of different concentrations of 
anesthetics (B: dexmedetomidine, C: propofol, D: sevoflurane). DEX: dexmedetomidine, PROP: propofol, SEVO: sevoflurane
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they did not use oxytocin to induce myometrial contrac-
tions. To the best of our knowledge, no previous studies 
have examined the effect of dexmedetomidine on oxy-
tocin-induced myometrial contraction in isolated myo-
metrium. In the present in vitro study, dexmedetomidine 
did not augment oxytocin-induced myometrial contrac-
tion. Oxytocin was used in this study at 20 nM so as to 
potentiate myometrial contraction. It is well known that 
oxytocin increases spontaneous myometrial contraction 
[35]. The reason for the difference was that oxytocin 
had a stronger effect on myometrial contraction than did 
dexmedetomidine.
In our in vivo study, dexmedetomidine increased the 
AUC, but no significant differences in AUC induced by 
propofol or sevoflurane were observed. Many hormones 
and humoral factors affect the myometrial contraction 
mechanism similar to oxytocin; thus, there may be mecha-
nisms that involve inhibition of myometrial relaxation. The 
above reasons explain the differences in the results of the 
present in vitro and in vivo studies.
Dexmedetomidine, a potent and highly selective 
α2-adrenoceptor agonist, has central and peripheral 
mechanisms of action. It has been suggested that α2-
adrenoceptor activation releases arachidonic acid in vascu-
lar smooth muscle [23]. Arachidonic acid inhibits MLCP 
and increases the  Ca2+ sensitivity of contractile elements 
[36]. Although the effect of dexmedetomidine on myome-
trial contraction remains unclear, dexmedetomidine may 
augment myometrial contraction via the same mechanism. 
It is well known that indomethacin inhibits cyclooxyge-
nase in the arachidonic acid cascade. In the presence of 
indomethacin, myometrial contraction induced by oxy-
tocin was inhibited, suggesting that arachidonic acid plays 
a role in the mechanism by which dexmedetomidine aug-
ments myometrial contractions.
In vascular smooth muscle, contraction is regulated 
by changes in both the intracellular  Ca2+ concentration 
and myofilament  Ca2+ sensitivity. Several studies have 
reported that contractions in uterine smooth muscle are 
regulated by changes in intracellular  Ca2+ concentra-
tions [13, 37]. In contrast, myofilament  Ca2+ sensitivity 
has not been studied. Thus, the reason why propofol and 
sevoflurane did not augment myometrial contractions was 
investigated from the perspective of myofilament  Ca2+ 
Fig. 6  Effects of anesthetic 
agents on in vitro oxytocin-
induced contractions in the 
myometrium of pregnant rats 
(n = 10). (A) Ratio of AUC (% 
of oxytocin [20 nM]); (B) Ratio 
of frequency (% of oxytocin 
[20 nM]). AUC: area under the 
curve, * P < 0.05
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sensitivity. In the present study, propofol did not affect 
oxytocin-induced MYPT1 phosphorylation, whereas sevo-
flurane attenuated oxytocin-induced MYPT1 phosphoryla-
tion. The mechanism of the inhibitory effect of volatile 
anesthetics on myometrial contraction may differ from that 
of intravenous anesthetics.
In the present in vivo study, dexmedetomidine enhanced 
oxytocin-induced myometrial contraction. This suggests 
that dexmedetomidine enhances myometrial contraction and 
reduces the amount of bleeding during or after cesarean sec-
tion. Further studies will be needed to fully characterize the 
effects of anesthetic agents on myometrial contraction.
Fig. 7  Effects of anesthetics on in  vivo oxytocin-induced contractions in the myometrium of pregnant rats (n = 8). (A) AUC: area under the 
curve; (B) Frequency of contractions. * P < 0.05
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There are several limitations in the present study. First, 
the sedation level of the rats might have differed between 
anesthetic groups. Although 1 MAC of sevoflurane (2.3%) 
was used in some previous studies [38], the dose of propo-
fol or dexmedetomidine necessary to obtain a sedation 
level similar to that of 1 MAC of sevoflurane is unclear. A 
preliminary experiment was carried out to investigate the 
minimum concentration needed to sedate rats. The sedative 
level was evaluated in reference to the method of a previ-
ous study [39]. Second, although myofilament  Ca2+ sen-
sitivity was investigated as the mechanism by which the 
anesthetic agents regulate myometrial contraction, intra-
cellular  Ca2+ concentrations were not investigated in this 
study. It has been reported that myometrial contractions are 
regulated by changes in intracellular  Ca2+ concentrations 
through VDCCs, but the involvement of myofilament  Ca2+ 
sensitivity is unclear. Accordingly, the involvement of myo-
filament  Ca2+ sensitivity was examined in the present study.
In summary, this study demonstrated that dexme-
detomidine enhances oxytocin-induced contraction in 
the myometrium of pregnant rats, whereas propofol and 
sevoflurane attenuate contraction. The mechanism under-
lying the suppression of myometrial contraction differed 
between propofol and sevoflurane. Inhibition of myofila-
ment  Ca2+ sensitivity may have inhibited the myometrial 
contraction induced by sevoflurane. Arachidonic acid may 
play an important role in the enhancement of myometrial 
contraction induced by dexmedetomidine via enhance-
ment of myofilament  Ca2+ sensitivity. Dexmedetomidine 
could thus be used as a sedative agent after fetal deliv-
ery to promote uterine muscle contraction and suppress 
bleeding.
Fig. 8  Effect of indomethacin 
(5 mg/kg) on myometrial con-
traction enhanced by dexme-
detomidine (n = 6). AUC: area 
under the curve, * P < 0.05
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Fig. 9  Western blot analysis (n = 6). MYPT1: myosin phosphatase targeting subunit 1, p-MYPT1: phosphorylated MYPT 1, OXY: oxytocin 
(20 nM), PROP: propofol  (10−5 M), SEVO: sevoflurane (5.0%), Y27632: Rho-kinase inhibitor  (10−6 M), * P < 0.05
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